1. Home
  2. CUE vs MCHX Comparison

CUE vs MCHX Comparison

Compare CUE & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • MCHX
  • Stock Information
  • Founded
  • CUE 2014
  • MCHX 2003
  • Country
  • CUE United States
  • MCHX United States
  • Employees
  • CUE N/A
  • MCHX N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • MCHX Business Services
  • Sector
  • CUE Health Care
  • MCHX Consumer Discretionary
  • Exchange
  • CUE Nasdaq
  • MCHX Nasdaq
  • Market Cap
  • CUE 91.9M
  • MCHX 84.3M
  • IPO Year
  • CUE 2018
  • MCHX 2004
  • Fundamental
  • Price
  • CUE $1.42
  • MCHX $2.02
  • Analyst Decision
  • CUE Strong Buy
  • MCHX
  • Analyst Count
  • CUE 5
  • MCHX 0
  • Target Price
  • CUE $5.00
  • MCHX N/A
  • AVG Volume (30 Days)
  • CUE 261.2K
  • MCHX 32.8K
  • Earning Date
  • CUE 03-10-2025
  • MCHX 03-13-2025
  • Dividend Yield
  • CUE N/A
  • MCHX N/A
  • EPS Growth
  • CUE N/A
  • MCHX N/A
  • EPS
  • CUE N/A
  • MCHX N/A
  • Revenue
  • CUE $9,532,000.00
  • MCHX $48,594,000.00
  • Revenue This Year
  • CUE $73.11
  • MCHX N/A
  • Revenue Next Year
  • CUE $11.02
  • MCHX $4.63
  • P/E Ratio
  • CUE N/A
  • MCHX N/A
  • Revenue Growth
  • CUE 149.53
  • MCHX N/A
  • 52 Week Low
  • CUE $0.45
  • MCHX $1.11
  • 52 Week High
  • CUE $2.37
  • MCHX $2.40
  • Technical
  • Relative Strength Index (RSI)
  • CUE 55.26
  • MCHX 55.49
  • Support Level
  • CUE $1.22
  • MCHX $1.88
  • Resistance Level
  • CUE $1.50
  • MCHX $2.04
  • Average True Range (ATR)
  • CUE 0.12
  • MCHX 0.09
  • MACD
  • CUE -0.01
  • MCHX 0.00
  • Stochastic Oscillator
  • CUE 73.33
  • MCHX 85.71

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About MCHX Marchex Inc. Class B

Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.

Share on Social Networks: